HomeREGULATORY
REGULATORY

Chuikyo OKs Bavencio, Maviret, Ibrance and More for Listing on Nov. 22
(Nov.15.2017)

The health ministry’s key reimbursement panel on November 15 gave its thumbs-up to the NHI price listing of a slew of new medicines on November 22, including Japan’s first PD-L1 inhibitor Bavencio (avelumab) and AbbVie’s eight-week hepatitis C therapy Maviret (glecaprevir + pibrentasvir) ...
(LOG IN FOR FULL STORY)